Annexon Stock

Annexon ROE

The Return on Equity (ROE) of Annexon (ANNX) as of Aug 16, 2026 is -97.66 %. In the previous year, Return on Equity (ROE) was -47.15 % — a change of 107.12% (lower).

ROE

-97.66 %

YoY

107.12%

Last updated:

In 2026, Annexon's return on equity (ROE) was -97.66 %, a 107.12% increase from the -47.15 % ROE in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Annexon Stock analysis

What does Annexon do? Annexon Inc is a biopharmaceutical company based in South San Francisco, California. It was founded in 2011 by Doug Love, Ted Love, and Arnon Rosenthal, who had previously worked at major pharmaceutical companies such as Genentech and Novartis. The company's main goal is to develop new treatment options for neurodegenerative diseases, focusing on the development of drugs that target the autophagy process in cells to reduce damage to nerve cells and alleviate symptoms. Annexon Inc has two divisions, Annexon Biosciences and Annexon Clinical, with partnerships with renowned pharmaceutical companies to advance drug development. Its main product is ANX005, a therapeutic antibody protein that targets the role of the complement system in neurodegenerative diseases. Annexon Inc has received multiple awards for its work and innovations and has a dedicated team of scientists and executives committed to improving the lives of people with neurodegenerative diseases. Annexon is one of the most popular companies on Eulerpool.

ROE Details

Decoding Annexon's Return on Equity (ROE)

Annexon's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Annexon's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Annexon's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Annexon’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Annexon stock

Return on Equity (ROE) of Annexon is -97.66 % in 2026.

Return on Equity (ROE) of Annexon changed from -47.15 % to -97.66 %, representing a 107.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Annexon since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Annexon with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Annexon

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Annexon